From Founder-Led to Commercialization-Focused

BioNTech SE (BNTX) has appointed Guido Oelrichs, who led Swedish Orphan Biovitrum AB (STO:SOBI) since 2017, as its next CEO. Co-founders Ugur Sahin and Chief Medical Officer Özlem Türeci will step down from management at the end of their current terms in late 2026 to establish a next-generation messenger ribonucleic acid (mRNA) company. BioNTech plans to transfer related technologies and rights and conclude an agreement by the first half of 2026, receiving minority equity, milestone payments, and royalties. This marks a shift from a research-driven organization to one where founders focus on early innovation, while Oelrichs will oversee late-stage clinical trials, approvals, production, and sales.

Pumitamig as the Key Asset in the Transition

The core asset in this new structure is pumitamig (BNT327/BMS-986545), which currently lacks a brand name and is a bispecific antibody that simultaneously targets PD-L1 and vascular endothelial growth factor A (VEGF-A). In a Phase 3 trial (NCT06712355) for first-line, extensive-stage small cell lung cancer, pumitamig in combination with chemotherapy is being directly compared to the standard of care, which is Tecentriq (atezolizumab, PD-L1) in combination with chemotherapy. The Phase 3 portion of a Phase 2/3 trial (NCT06712316) in non-small cell lung cancer compares pumitamig in combination with Keytruda (pembrolizumab, PD-1) to a control arm. Pumitamig is a clinical-stage asset that has not yet received FDA, EMA, or PMDA marketing approval. BioNTech aims to conduct 15 late-stage cancer trials and release six sets of data by the end of 2026.

BMS Funding and Competitive Landscape Will Determine Value

Bristol Myers Squibb (BMY) entered into a global co-development and co-commercialization agreement for pumitamig in June 2025, with an upfront payment of USD 1.5 billion, USD 2.0 billion in unconditional payments by 2028, and up to USD 7.6 billion in development, regulatory, and commercial milestone payments. The two companies will share development and manufacturing costs and global profits on a roughly 50/50 basis, with BioNTech recognizing sales in the U.S. and BMS recognizing sales outside the U.S. Competing assets include ivonescimab, a PD-1/VEGF bispecific antibody from Summit Therapeutics (SMMT) and Akeso, as well as Keytruda from Merck & Co. (MRK) and Tecentriq from Roche Holding AG (SIX:ROG). Therefore, while large-scale clinical expansion increases external validation and market access, a lack of differentiation in survival and safety in head-to-head trials could also increase costs.

An Operational Move Targeting the Large Oncology Market

IQVIA forecasts that global oncology spending will increase from USD 252 billion in 2024 to USD 441 billion in 2029. BioNTech's current marketed product is Comirnaty (tozinameran, a SARS-CoV-2 spike protein mRNA vaccine), which was co-developed with Pfizer (PFE) and granted full FDA approval on August 23, 2021. As of March 31, 2026, the company's cash and cash equivalents and marketable securities totaled EUR 16.8 billion, but its first-quarter net loss was EUR 531.9 million, making capital efficiency in late-stage oncology development critical. Oelrichs' experience in acquiring rare disease products and expanding global sales will be evaluated based on how quickly clinical data translates into regulatory approvals, reimbursement, and actual sales.